Abstract #1928
In vivo imaging of Tau pathology using Multi-Parametric Quantitative MRI
Jack A Wells 1 , James M O'Callaghan 1 , Holly E Holmes 1 , Nicholas M Powell 1 , Bernard Siow 1 , F Torrealdea 2 , Marilena Rega 2 , Ozama Ismail 1 , Simon Walker-Samuel 1 , Xavier Golay 2 , Simon Richardson 1 , Adam J Schwarz 3 , Michael J O'Neil 4 , Emily C Collins 3 , Niall Colgan 1 , and Mark F Lythgoe 1
1
Centre for Advanced Biomedical Imaging, UCL,
London, London, United Kingdom,
2
Institute
of Neurology, UCL, London, United Kingdom,
3
Lilly
Corporate Centre, Eli Lilly & Co. Ltd, Indianapolis,
United States,
4
Eli
Lilly & Co. Ltd Erl Wood Manor, Windlesham, Surrey,
United Kingdom
In this study, we target diverse and specific components
of tau pathology by applying multi-parametric MRI to the
rTg4510 model of Alzheimers disease. We investigate how
elevated tau expression affects: i) cerebral blood flow
using arterial spin labelling ii) chemical exchange
saturation transfer iii) brain glucose uptake using
gluco-CEST iv) diffusion tensor imaging and v) brain
atrophy using tensor based morphometry. Each technique
can unambiguously discriminate tau pathology from
healthy control subjects in selective white and grey
matter regions, providing a platform for the
longitudinal assessment of experimental treatments using
non-invasive imaging techniques.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
